Ganeden Biotech, a manufacturer and marketer of probiotics, has announced the issuance of a United States patent that covers the use of all Bacillus coagulans in all coffee, tea, and cereal. The issuance of patent #US 8,697,055 B2 protects the use of all Bacillus coagulans probiotic strains including GanedenBC30 in coffee, tea, and cereal applications.
Spore forming probiotic organisms, such as Bacillus coagulans, are the only probiotics that have the ability to withstand harsh manufacturing processes, especially those required to make hot tea, coffee, and cereal. The effectiveness of these organisms can be linked to its naturally occurring layer of organic material (spore), which protects the genetic core of the bacteria throughout the manufacturing process and the transit into the gut.
“This patent goes a long way toward supporting our partners in their quest to launch new brands and revolutionize existing ones,” said Andy Lefkowitz, CEO of Ganeden Biotech. “When combined with the FDA’s No Objection letter on GRAS (safety), 17 studies published in peer reviewed journals, over 100 patents issued around the world, and the pending issuance of the first monograph by the USP, we have again demonstrated our commitment to science-based probiotic innovation.”